<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2021-1-73-78</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1103</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Новые аспекты лечения боли при острых и хронических воспалительных синдромах</article-title><trans-title-group xml:lang="en"><trans-title>New aspects of pain management in acute and chronic inflammatory syndromes</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5382-6357</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Амирджанова</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Amirdjanova</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вера Николаевна Амирджанова</p><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>Vera Nikolaevna Amirdzhanova</p><p>34A, Kashirskoe shosse, Moscow 115522</p></bio><email xlink:type="simple">amirver@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1391-0711</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каратеев</surname><given-names>А. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Karateev</surname><given-names>A. Е.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>18</day><month>02</month><year>2021</year></pub-date><volume>15</volume><issue>1</issue><fpage>73</fpage><lpage>78</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Амирджанова В.Н., Каратеев А.Е., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Амирджанова В.Н., Каратеев А.Е.</copyright-holder><copyright-holder xml:lang="en">Amirdjanova V.N., Karateev A.Е.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1103">https://mrj.ima-press.net/mrj/article/view/1103</self-uri><abstract><p>Эффективный контроль боли – одна из первоочередных и наиболее важных задач медицинской практики. Нестероидные противовоспалительные препараты (НПВП) являются основой лечения острых и хронических воспалительных болевых синдромов. Особый интерес представляет группа пациентов с низким риском развития кардиоваскулярных и низким или умеренным риском желудочно-кишечных осложнений, которым могут быть рекомендованы любые НПВП. Их выбор может зависеть от продолжительности и выраженности воспалительного процесса. Наиболее мощным обезболивающим потенциалом обладают неселективные ингибиторы циклооксигеназы – диклофенак и кетопрофен. Современные технологии создают широкие возможности для модификации действующего вещества и совершенствования лекарственной формы НПВП с целью повышения быстроты действия и выраженности обезболивающего и противовоспалительного эффекта. В новой форме диклофенака (Диалрапид саше) натриевая соль была заменена на калиевую, что обеспечило высокую скорость как абсорбции активного вещества, так и действия, сравнимую с таковой при внутримышечном введении препарата, а также расширило возможности его применения для купирования острой боли и рецидивов боли при обострении хронических воспалительных заболеваний. Существенно изменило фармакодинамику кетопрофена включение в его формулу лизиновой соли. В отличие от обычного кетопрофена, его лизиновые соли (Артрозилен и ОКИ) – быстрорастворимые соединения с нейтральным рН, не раздражающие слизистую оболочку желудочно-кишечного тракта, что позволяет использовать их для длительного лечения хронических воспалительных болевых синдромов.</p></abstract><trans-abstract xml:lang="en"><p>Effective pain control is one of the first and most important challenges in medical practice. Non-steroidal anti-inflammatory drugs (NSAIDs) are the cornerstone of treatment for acute and chronic inflammatory pain syndromes. Of particular interest is a group of patients with a low risk of cardiovascular development and a low to moderate risk of gastrointestinal complications, for whom any NSAID may be recommended. Their choice may depend on the duration and severity of the inflammatory process. The most high analgesic potential have non-selective inhibitors of cyclooxygenase – diclofenac and ketoprofen. Modern technologies give great opportunities for modifying the active substance of NSAIDs and improvement of the drug dosage form in order to hasten their effects and enhance analgesic and anti-inflammatory effect of drugs. In the new form of diclofenac (Dialrapid sachet), sodium salt was replaced by potassium salt, which provided a high rate of both absorption of the active substance and action, comparable to that with intramuscular administration of the drug. It also expanded the possibilities of its use for acute pain and relapses of pain relief in exacerbation of chronic inflammatory diseases. The inclusion of lysine salt significantly changed the pharmacodynamics of ketoprofen. Unlike conventional ketoprofen, its lysine salts (Artrozilen and OKИ) are fast-dissolving compounds with neutral pH that do not irritate the mucous membrane of the gastrointestinal tract, which makes them suitable for long-term treatment of chronic inflammatory pain syndromes.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>нестероидные противовоспалительные препараты</kwd><kwd>Диалрапид</kwd><kwd>Артрозилен</kwd><kwd>ОКИ</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Non-steroidal anti-inflammatory drugs (NSAIDs)</kwd><kwd>Dialrapid</kwd><kwd>Artrozilen and OKИ</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Статья спонсируется компанией CSC</funding-statement><funding-statement xml:lang="en">This article has been supported by CSC</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Кукушкин МЛ. Алгоритмы диагностики и лечения боли в спине. Русский медицинский журнал. 2014;(11):844-8.</mixed-citation><mixed-citation xml:lang="en">Kukushkin ML. Algorithms for diagnosis and treatment of back pain. Russkii meditsinskii zhurnal. 2014;(11):844-8. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Malanga G, Wolff E. Evidence-informed management of chronic low back pain with nonsteroidal anti-inflammatory drugs, muscle relaxants, and simple analgesics. Spine J. 2008 Jan–Feb;8(1):173–84. doi: 10.1016/j.spinee.2007.10.013.</mixed-citation><mixed-citation xml:lang="en">Malanga G, Wolff E. Evidence-informed management of chronic low back pain with nonsteroidal anti-inflammatory drugs, muscle relaxants, and simple analgesics. Spine J. 2008 Jan–Feb;8(1):173–84. doi: 10.1016/j.spinee.2007.10.013.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lee C, Straus WL, Balshaw R, et al. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum. 2004 Oct 15;51(5):746-54. doi: 10.1002/art.20698.</mixed-citation><mixed-citation xml:lang="en">Lee C, Straus WL, Balshaw R, et al. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum. 2004 Oct 15;51(5):746-54. doi: 10.1002/art.20698.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective nonsteroidal antiinflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008 Apr;12(11):1-278, iii. doi: 10.3310/hta12110.</mixed-citation><mixed-citation xml:lang="en">Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective nonsteroidal antiinflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008 Apr;12(11):1-278, iii. doi: 10.3310/hta12110.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Stam W, Jansen J, Taylor S. Efficacy of etoricoxib, celecoxib, lumiracoxib, nonselective NSAIDs, and acetaminophen in osteoarthritis: a mixed treatment comparison. Open Rheumatol J. 2012;6:6-20. doi: 10.2174/1874312901206010006. Epub 2012 Apr 3.</mixed-citation><mixed-citation xml:lang="en">Stam W, Jansen J, Taylor S. Efficacy of etoricoxib, celecoxib, lumiracoxib, nonselective NSAIDs, and acetaminophen in osteoarthritis: a mixed treatment comparison. Open Rheumatol J. 2012;6:6-20. doi: 10.2174/1874312901206010006. Epub 2012 Apr 3.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Sieper J, Klopsch T, Richter M, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis. 2008 Mar; 67(3):323–9. Epub 2007 Jul 6.</mixed-citation><mixed-citation xml:lang="en">Sieper J, Klopsch T, Richter M, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis. 2008 Mar; 67(3):323–9. Epub 2007 Jul 6.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Roelofs PD, Deyo RA, Koes BW, et al. Nonsteroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD000396. doi: 10.1002/14651858.CD000396.pub3.</mixed-citation><mixed-citation xml:lang="en">Roelofs PD, Deyo RA, Koes BW, et al. Nonsteroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD000396. doi: 10.1002/14651858.CD000396.pub3.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ. Анальгетическая терапия в ревматологии: путешествие между Сциллой и Харибдой. Клиническая фармакология и терапия 2003;12(1):64–9.</mixed-citation><mixed-citation xml:lang="en">Nasonov EL. Analgesic therapy in rheumatology: a journey between Scylla and Charybdis. Klinicheskaya farmakologiya i terapiya 2003;12(1):64–9. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев АЕ, Насонов ЕЛ, Ивашкин ВТ и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018; 56(Прил 1):1-29.</mixed-citation><mixed-citation xml:lang="en">Karateev AE, Nasonov EL, Ivashkin VT, et al. Rational use of nonsteroidal antiinflammatory drugs. Clinical recommendations. Nauchno-prakticheskaya revmatologiya. 2018;56(Pril 1):1-29. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Chen C, Bujanover S, Kareht S, Rapoport AM. Differential Pharmacokinetics of Diclofenac Potassium for Oral Solution vs Immediate-Release Tablets From a Randomized Trial: Effect of Fed and Fasting Conditions. Headache. 2015 Feb;55(2):265-75. doi: 10.1111/head.12483. Epub 2014 Dec 24.</mixed-citation><mixed-citation xml:lang="en">Chen C, Bujanover S, Kareht S, Rapoport AM. Differential Pharmacokinetics of Diclofenac Potassium for Oral Solution vs Immediate-Release Tablets From a Randomized Trial: Effect of Fed and Fasting Conditions. Headache. 2015 Feb;55(2):265-75. doi: 10.1111/head.12483. Epub 2014 Dec 24.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Efficacy of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study with diclofenac potassium tablets and placebo. Poster XII. Congress of International Headache Society (HIS), Kyoto-Japan, October 9-12, 2005.</mixed-citation><mixed-citation xml:lang="en">Efficacy of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study with diclofenac potassium tablets and placebo. Poster XII. Congress of International Headache Society (HIS), Kyoto-Japan, October 9-12, 2005.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Moran M. Double-blind Comparison of Diclofenac Potassium, Ibuprofen and Placebo in the treatment of ankle sprains. J Int Med Res. Mar-Apr 1991;19(2):121-30. doi: 10.1177/030006059101900205..</mixed-citation><mixed-citation xml:lang="en">Moran M. Double-blind Comparison of Diclofenac Potassium, Ibuprofen and Placebo in the treatment of ankle sprains. J Int Med Res. Mar-Apr 1991;19(2):121-30. doi: 10.1177/030006059101900205.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Verfaillie G, Knape S, Corne L. A case of fatal necrotizing fasciitis after intramuscular administration of diclofenac. Eur J Emerg Med. 2002 Sep;9(3):270–3.</mixed-citation><mixed-citation xml:lang="en">Verfaillie G, Knape S, Corne L. A case of fatal necrotizing fasciitis after intramuscular administration of diclofenac. Eur J Emerg Med. 2002 Sep;9(3):270–3.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Rossi L, Conen D. Intramuscular injections-an outdated form of administration? 6 cases of Staphylococcus aureus sepsis following intramuscular injections. Schweiz Med Wochenschr. 1995 Aug 8;125(31–32):1477–82.</mixed-citation><mixed-citation xml:lang="en">Rossi L, Conen D. Intramuscular injections-an outdated form of administration? 6 cases of Staphylococcus aureus sepsis following intramuscular injections. Schweiz Med Wochenschr. 1995 Aug 8;125(31–32):1477–82.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Rotman-Pikielny P, Levy Y, Eyal A, Shoenfeld Y. Pyomyositis or «injectiositis»– Staphylococcus aureus multiple abscesses following intramuscular injections. Isr Med Assoc J. 2003 Apr;5(4):295–6.</mixed-citation><mixed-citation xml:lang="en">Rotman-Pikielny P, Levy Y, Eyal A, Shoenfeld Y. Pyomyositis or «injectiositis»– Staphylococcus aureus multiple abscesses following intramuscular injections. Isr Med Assoc J. 2003 Apr;5(4):295–6.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев АЕ, Погожева ЕЮ, Филатова ЕС и др. Есть ли альтернатива внутримышечным инъекциям диклофенака для контролирования сильной боли? Результаты рандомизированного, контролируемого частично слепого исследования ФОРСАЖ. Научно-практическая ревматология. 2020;58(4):387-94.</mixed-citation><mixed-citation xml:lang="en">Karateev AE, Pogozheva EYu, Filatova ES, et al. Is there an alternative to intramuscular injections of diclofenac to control severe pain? The results of a randomized controlled partially blind study, the fast and the FORSAGE. Nauchno-prakticheskaya revmatologiya. 2020; 58(4):387-94. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев АЕ, Погожева ЕЮ, Лила АМ и др. Ретроспективное наблюдательное исследование ДРАйВ (Действенная и Рациональная Анальгезия: Выбор). Русский медицинский журнал. 2019;(9):62-6.</mixed-citation><mixed-citation xml:lang="en">Karateev AE, Pogozheva EYu, Lila AM, et al. Retrospective observational study DRIVE (Effective and Rational Analgesia: the Choice). Russkii meditsinskii zhurnal. 2019; (9):62-6. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Sarzi-Puttini P, Atzeni F, Lanata L, et al. Pain and ketoprofen: what is its role in clinical practice? Reumatismo. Jul-Sep 2010;62(3): 172-88. doi: 10.4081/reumatismo.2010.172.</mixed-citation><mixed-citation xml:lang="en">Sarzi-Puttini P, Atzeni F, Lanata L, et al. Pain and ketoprofen: what is its role in clinical practice? Reumatismo. Jul-Sep 2010;62(3): 172-88. doi: 10.4081/reumatismo.2010.172.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Le Loet X. Safety of ketoprofen in the elderly: a prospective study on 20,000 patients. Scand J Rheumatol Suppl. 1989; 83:21-7. doi: 10.3109/03009748909101474.</mixed-citation><mixed-citation xml:lang="en">Le Loet X. Safety of ketoprofen in the elderly: a prospective study on 20,000 patients. Scand J Rheumatol Suppl. 1989; 83:21-7. doi: 10.3109/03009748909101474.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Чичасова НВ, Иммаметдинова ГР, Каратеев АЕ и др. Эффективность и безопасность кетопрофена (кетонал) при ревматоидном артрите (клинико-эндоскопическое исследование). Научно-практическая ревматология. 2001;(1):47-52.</mixed-citation><mixed-citation xml:lang="en">Chichasova NV, Immametdinova GR, Karateev AE, et al. Efficacy and safety of Ketoprofen (Ketonal) in rheumatoid arthritis (clinical and endoscopic examination). Nauchno-prakticheskaya revmatologiya. 2001;(1):47-52. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Marmo E, Ottavo R, Giordano L, et al. Experimental assessment of some pharmacodynamic features of ketoprofen lysine. Pain relief activity, antipyretic effects, antiinflammatory activity, antiplatelet aggregation activity and interference with the biosynthesis of prostaglandins. Arch Sci Med (Torino). Jul-Sep 1980;137(3):387-404.</mixed-citation><mixed-citation xml:lang="en">Marmo E, Ottavo R, Giordano L, et al. Experimental assessment of some pharmacodynamic features of ketoprofen lysine. Pain relief activity, antipyretic effects, antiinflammatory activity, antiplatelet aggregation activity and interference with the biosynthesis of prostaglandins. Arch Sci Med (Torino). Jul-Sep 1980;137(3):387-404.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">D’Arienzo M. Pennisi M, Zanolo G, Borsa M. Ketoprofen lysine: ketoprofen serum levels and analgesic activity. Drugs Exp Clin Res. 1984;10:863-6.</mixed-citation><mixed-citation xml:lang="en">D’Arienzo M. Pennisi M, Zanolo G, Borsa M. Ketoprofen lysine: ketoprofen serum levels and analgesic activity. Drugs Exp Clin Res. 1984;10:863-6.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kokki H. Ketoprofen pharmacokinetics, efficacy, and tolerability in pediatric patients. Paediatr Drugs. 2010 Oct 1;12(5):313-29. doi: 10.2165/11534910-000000000-00000.</mixed-citation><mixed-citation xml:lang="en">Kokki H. Ketoprofen pharmacokinetics, efficacy, and tolerability in pediatric patients. Paediatr Drugs. 2010 Oct 1;12(5):313-29. doi: 10.2165/11534910-000000000-00000.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев АЕ, Журавлева МВ, Алексеев ВВ и др. Эффективность комбинации различных лекарственных форм кетопрофена лизиновой соли (Артрозилен®) у пациентов с выраженной мышечно-скелетной болью в реальной клинической практике. Результаты исследования КУЛОН (Кетопрофен: Удовлетворенность Лечением и Оценка Нежелательных явлений). Клиническая фармакология и терапия. 2013;(4):23-30.</mixed-citation><mixed-citation xml:lang="en">Karateev AE, Zhuravleva MV, Alekseev VV, et al. The effectiveness of the combination of various dosage forms of Ketoprofen lysine salt (Arthrosylene®) in patients with severe musculoskeletal pain in real clinical practice. Results of the KULON study (Ketoprofen: Treatment Satisfaction and assessment of Adverse events). Klinicheskaya farmakologiya i terapiya. 2013;(4):23-30. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Амирджанова ВН. Нестероидные противовоспалительные препараты: нелегкий выбор обезболивания при операциях на суставах. Научно-практическая ревматология. 2017;55(5):555-9.</mixed-citation><mixed-citation xml:lang="en">Amirdzhanova VN. Nonsteroidal antiinflammatory drugs: the difficult choice of pain relief for joint operations. Nauchnoprakticheskaya revmatologiya. 2017;55(5): 555-9. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Cimini A, Brandolini L, Gentile R, et al. Gastroprotective effects of L-lysine salification of ketoprofen in ethanol-injured gastric mucosa. J Cell Physiol. 2015 Apr;230(4): 813-20. doi: 10.1002/jcp.24809.</mixed-citation><mixed-citation xml:lang="en">Cimini A, Brandolini L, Gentile R, et al. Gastroprotective effects of L-lysine salification of ketoprofen in ethanol-injured gastric mucosa. J Cell Physiol. 2015 Apr;230(4): 813-20. doi: 10.1002/jcp.24809.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
